Your browser is no longer supported. Please, upgrade your browser.
Settings
SGYP Synergy Pharmaceuticals, Inc. daily Stock Chart
SGYP [NASD]
Synergy Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.56 Insider Own0.29% Shs Outstand248.04M Perf Week-
Market Cap- Forward P/E- EPS next Y-0.43 Insider Trans- Shs Float247.20M Perf Month-
Income- PEG- EPS next Q-0.13 Inst Own15.36% Short Float8.90% Perf Quarter-
Sales41.35M P/S- EPS this Y47.00% Inst Trans- Short Ratio- Perf Half Y-
Book/sh-0.39 P/B- EPS next Y18.90% ROA- Target Price2.00 Perf Year-
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range- - - Perf YTD-
Dividend- P/FCF- EPS past 5Y- ROI- 52W High- Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low- ATR-
Employees291 Current Ratio- Sales Q/Q121.70% Oper. Margin- RSI (14)- Volatility- -
OptionableYes Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume- Prev Close-
ShortableNo LT Debt/Eq- Earnings- Payout- Avg Volume- Price-
Recom3.00 SMA20- SMA50- SMA200- Volume0 Change-
Apr-12-19 03:00PM  FINAL DEADLINE: Bronstein, Gewirtz & Grossman, LLC - UXIN, SGYP & MHLD GlobeNewswire
02:20PM  SHAREHOLDER ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Synergy Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
Apr-11-19 05:23PM  FRIDAY DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Synergy Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire
04:45PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Synergy Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline - SGYP ACCESSWIRE
Apr-10-19 11:05AM  DEADLINE FRIDAY REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Synergy Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Business Wire
Apr-09-19 10:24AM  SGYP & MHLD - Class Action Bronstein, Gewirtz & Grossman, LLC ACCESSWIRE
Apr-08-19 06:28PM  DEADLINE FRIDAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Synergy Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Business Wire
02:56PM  SYNERGY INVESTORS APRIL 12th DEADLINE ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Synergy Pharmaceuticals Inc.; Encourages Investors With Losses In Excess of $100K to Contact the Firm SGYP Business Wire
Apr-05-19 10:23AM  Class Action Bronstein, Gewirtz & Grossman, LLC - SGYP & MHLD ACCESSWIRE
Apr-03-19 10:22AM  Class Action Reminder Bronstein, Gewirtz & Grossman, LLC - SGYP & MHLD ACCESSWIRE
Mar-29-19 03:00PM  Bronstein, Gewirtz & Grossman, LLC Class Action Update - UXIN, SGYP & MHLD GlobeNewswire
10:57AM  Bronstein, Gewirtz & Grossman, LLC Class Action Reminder - UXIN, SGYP & MHLD ACCESSWIRE
Synergy Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat gastrointestinal diseases and disorders. Its lead product is plecanatide, a novel uroguanylin based gastrointestinal platform that is traded under the TRULANCE name for the treatment of chronic idiopathic constipation and irritable bowel syndrome. The company also develops dolcanatide to treat mild-to-moderate ulcerative colitis. It has a licensing agreement with Cipher Pharmaceuticals Inc. to develop, market, distribute, and sell TRULANCE in Canada. Synergy Pharmaceuticals Inc. is headquartered in New York, New York. On December 12, 2018, Synergy Pharmaceuticals Inc. along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.